AI Prospecting for Viatris
Company data:
Company size:
33000 employeesWebsite URL:
https://www.viatris.comIndustry
PharmaceuticalsHeadquarters:
1000 Mylan Boulevard, Canonsburg, Pennsylvania, USAInvestment round:
NASDAQ: VTRSARR:
$16 billionKey stakeholders
These are the current top-level decision-makers at the company and their LinkedIn profiles. Check them for recent activity and updates
Latest news about Viatris
Here are some of the most recent media mentions. Use them in your sales prospecting to qualify a prospect's buyer intent and personalize outreach with the latest company updates
Viatris announced a quarterly dividend of $0.12 per share, payable on December 13, 2024, to shareholders recorded as of November 22, 2024. The company also reported Q3 2024 financial results, showing $3.8 billion in total revenues and a 3% operational revenue growth on a divestiture-adjusted basis[1][2][3].
Viatris announced an exclusive licensing agreement with Lexicon Pharmaceuticals for sotagliflozin in all markets outside the U.S. and Europe, expanding its cardiovascular disease portfolio. Sotagliflozin reduces cardiovascular risks in adults with heart failure or type 2 diabetes and other cardiovascular risk factors[1][3][4].
Viatris reported positive top-line results from a Phase 3 study of EFFEXOR® in Japanese adults with generalized anxiety disorder (GAD), announced on October 9, 2024[5].
Open job positions at Viatris
This company is actively hiring to fill these roles. Use this for sales prospecting if your solution assists, augments, or provides an alternative for the growing team and position.
1st shift Chemist
Senior Manager Regulatory CMC Strategy
Regulatory Strategist Director
